Loading...
Diabetic patients have higher BMD but greater risk for fragility fractures than do nondiabetics. Could diabetes medications account for this finding? In two studies, researchers investigated whether thiazolidinediones (TZDs) were linked to elevated fracture incidence.
In the original A Diabetes Outcome Progression Trial (ADOPT) — a comparison of the glucose-controlling effects of rosiglitazone (a TZD), glyburide, and metformin — a relatively high rate of fractures among rosiglitazone users was identified unexpectedly. In a supplementary study, investigators randomly assigned patients with recent diabetes diagnoses (who were naive to oral antidiabetic drugs) to one of the three drugs. Of 1840 female participants, 111 reported fractures during…